Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals insider plans to sell additional shares under Rule 144. A notice was filed to sell 2203 shares of common stock through Fidelity Brokerage Services LLC on or about 01/20/2026 on the NASDAQ market, with an aggregate market value of 43,603.76. The issuer had 126,525,218 common shares outstanding.
The 2203 shares to be sold were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, Nur Nicholson sold an additional 2618 common shares for gross proceeds of 58,086.09. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Apellis Pharmaceuticals.
David O. Watson filed a Form 144 notice to sell 2,475 shares of common stock through Fidelity Brokerage Services LLC on or about January 20, 2026 on NASDAQ. The shares to be sold have an aggregate market value of $48,987.43, compared with 126,525,218 shares outstanding. These securities were acquired as restricted stock that vested on January 16, 2026 as compensation from the issuer. In the prior three months, Watson sold 5,000, 5,000, and 5,780 shares of common stock for gross proceeds of $100,300.00, $122,450.00, and $128,242.01, respectively.
Apellis Pharmaceuticals insider Cedric Francois has filed a Form 144 to potentially sell 8,182 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $161,945.51 based on the figures in the notice. The stock was acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation.
The notice also reports that during the past three months, Francois sold 10,186 shares of common stock on 01/13/2026 for gross proceeds of $225,998.82. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
An APLS shareholder filed a notice of intent under Rule 144 to sell 1,334 common shares through Fidelity Brokerage Services LLC on 01/20/2026 on NASDAQ, with an aggregate market value of 26,403.73. These shares were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/16/2026.
Over the prior three months, Mark J. Delong sold 1,780 common shares on 01/13/2026 for gross proceeds of 39,493.22. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Pascal Deschatelets has filed a Form 144 notice relating to common stock of APLS, indicating an intent to sell 909 shares through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 01/20/2026. These 909 shares were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation.
The notice also reports that during the past three months, Deschatelets sold 2,277 common shares for gross proceeds of 50520.25. The filing lists 126,525,218 shares of this class outstanding, providing context for the size of the planned and recent sales.
A shareholder has filed a notice of proposed sale of 1,882 common shares through Fidelity Brokerage Services LLC on 01/20/2026, with an aggregate market value of 37,250.24, to be sold on NASDAQ. The filing shows that 126,525,218 common shares were outstanding. The shares to be sold were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation.
During the prior three months, Caroline R. Baumal sold 3,020 common shares on 01/05/2026 for gross proceeds of 77,096.67. The person signing the notice represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of Apellis Pharmaceuticals (APLS) common stock has filed a notice under Rule 144 to sell restricted shares. The filing covers the planned sale of 2,892 common shares through Fidelity Brokerage Services on NASDAQ around 01/20/2026, with an indicated aggregate market value of $57,241.07. These shares were acquired from the issuer as restricted stock vesting on 01/16/2026 as compensation.
The notice also lists prior sales of the issuer’s common stock during the past three months by the same seller: 10,000 shares on 10/21/2025 for gross proceeds of $280,300.00, and 3,856 shares on 01/13/2026 for gross proceeds of $85,553.84. The filing notes that there were 126,525,218 common shares outstanding at the time indicated.
James G. Chopas filed a Rule 144 notice to sell 726 common shares of the issuer. The planned sale is to be executed through Fidelity Brokerage Services LLC on NASDAQ, with an approximate aggregate market value of $14,369.65 and an approximate sale date of 01/20/2026. The shares to be sold were acquired on 01/16/2026 through restricted stock vesting as compensation from the issuer. The notice also reports that the issuer had 126,525,218 shares outstanding. During the past three months, Chopas previously sold 873 common shares for gross proceeds of $19,369.43.
Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported a sale of 873 shares of Apellis common stock on January 13, 2026 at a price of $22.1872 per share. According to the filing, this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026, meaning it was tied to an equity compensation event rather than an open-market discretionary sale. Following this transaction, Chopas beneficially owned 52,595 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals, Inc. (APLS) reported an insider tax-related share sale by its Chief Business & Strat Officer, Mark DeLong. On January 13, 2026, DeLong sold 1,780 shares of Apellis common stock at a price of $22.1872 per share. According to the footnotes, these shares were sold solely to cover tax withholding on Restricted Stock Units that were released on January 12, 2026. Following this transaction, DeLong beneficially owned 83,058 shares of Apellis common stock, which includes 893 shares acquired through the company’s employee stock purchase plan on April 30, 2025.